Evidence map›Paper›PMID 26584804›Full record

ReviewJournal of molecular evolution2015

Aptamers Selected by Cell-SELEX for Molecular Imaging.

Cheng Jin, Jing Zheng, Chunmei Li, Liping Qiu, Xiaobing Zhang, Weihong Tan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of molecular evolution, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Advances in the development of aptamer drug conjugates for targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017
    Review
  5. Review
  6. A Quarter Century of In Vitro Selection.Journal of molecular evolution · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cheng JinMolecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China.
Jing ZhengMolecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China.
Chunmei LiKey Laboratory of Luminescent and Real-Time Analytical Chemistry, Ministry of Education, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
Liping QiuMolecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China.
Xiaobing ZhangMolecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China. xbzhang@hnu.edu.cn.
Weihong TanMolecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering and College of Biology, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, 410082, China. tan@chem.ufl.edu.

Funding

Development of molecular probes for biomedical applicationsR01GM079359 · NIGMS · UNIVERSITY OF FLORIDA · PI TAN, WEIHONG · 2007 to 2016
$2.3M
Molecular Target for Liver Cancer Diagnosis and TherapyR01CA133086 · NCI · UNIVERSITY OF FLORIDA · PI LIU, CHEN · 2009 to 2013
$1.5M
NCI NIH HHS CA133086NCI NIH HHS R01 CA133086NIGMS NIH HHS GM079359NIGMS NIH HHS R01 GM079359
6 · The paper itself

Abstract

Conventional diagnostics for cancer rely primarily on anatomical techniques. However, these techniques cannot monitor the changes at the molecular level in normal cells, which possibly signal the onset of cancer at its very earliest stages. For accurate prediction of the carcinogenesis at the molecular level, targeting ligands have been used in combination with imaging probes to monitor this biological process. Among these targeting ligands, aptamers have high binding affinity to various targets ranging from small molecules to whole organisms, and, hence, exceptional recognition ability. Many recent studies have been reported on aptamer-based molecular imaging, clearly indicating its clinical and diagnostic utility. In this review, we will discuss some key results of these studies.

Indexed as

Aptamers, NucleotideMolecular ImagingAnimalsHumansMagnetic Resonance ImagingNeoplasmsOptical ImagingSELEX Aptamer TechniqueAptamers, NucleotideAptamerCancerMolecular imagingSELEXTargeting ligands

Identifiers

PMID26584804
PMCPMC5510553

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.